Computational drug repositioning for peripheral arterial disease: Prediction of anti-inflammatory and pro-angiogenic therapeutics

Liang Hui Chu, Brian H. Annex, Aleksander S Popel

Research output: Contribution to journalArticle

Abstract

Peripheral arterial disease (PAD) results from atherosclerosis that leads to blocked arteries and reduced blood flow, most commonly in the arteries of the legs. PAD clinical trials to induce angiogenesis to improve blood flow conducted in the last decade have not succeeded. We have recently constructed PADPIN, protein-protein interaction network (PIN) of PAD, and here we combine it with the drug-target relations to identify potential drug targets for PAD. Specifically, the proteins in the PADPIN were classified as belonging to the angiome, immunome, and arteriome, characterizing the processes of angiogenesis, immune response/inflammation, and arteriogenesis, respectively. Using the network-based approach we predict the candidate drugs for repositioning that have potential applications to PAD. By compiling the drug information in two drug databases DrugBank and PharmGKB, we predict FDA-approved drugs whose targets are the proteins annotated as anti-angiogenic and pro-inflammatory, respectively. Examples of pro-angiogenic drugs are carvedilol and urokinase. Examples of anti-inflammatory drugs are ACE inhibitors and maraviroc. This is the first computational drug repositioning study for PAD.

Original languageEnglish (US)
Article number179
JournalFrontiers in Pharmacology
Volume6
Issue numberAug
DOIs
StatePublished - 2015

Fingerprint

Drug Repositioning
Peripheral Arterial Disease
Anti-Inflammatory Agents
Pharmaceutical Preparations
Therapeutics
Arteries
Pharmaceutical Databases
Protein Interaction Maps
Proteins
Urokinase-Type Plasminogen Activator
Prodrugs
Angiotensin-Converting Enzyme Inhibitors
Leg
Atherosclerosis
Clinical Trials
Inflammation

Keywords

  • Angiogenesis
  • Bioinformatics
  • Cardiovascular disease
  • Computational drug repositioning
  • Drug-target network
  • Inflammation
  • Peripheral arterial disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Computational drug repositioning for peripheral arterial disease : Prediction of anti-inflammatory and pro-angiogenic therapeutics. / Chu, Liang Hui; Annex, Brian H.; Popel, Aleksander S.

In: Frontiers in Pharmacology, Vol. 6, No. Aug, 179, 2015.

Research output: Contribution to journalArticle

@article{2a7e4d7bd83d41dbaaf4b7b793c214d8,
title = "Computational drug repositioning for peripheral arterial disease: Prediction of anti-inflammatory and pro-angiogenic therapeutics",
abstract = "Peripheral arterial disease (PAD) results from atherosclerosis that leads to blocked arteries and reduced blood flow, most commonly in the arteries of the legs. PAD clinical trials to induce angiogenesis to improve blood flow conducted in the last decade have not succeeded. We have recently constructed PADPIN, protein-protein interaction network (PIN) of PAD, and here we combine it with the drug-target relations to identify potential drug targets for PAD. Specifically, the proteins in the PADPIN were classified as belonging to the angiome, immunome, and arteriome, characterizing the processes of angiogenesis, immune response/inflammation, and arteriogenesis, respectively. Using the network-based approach we predict the candidate drugs for repositioning that have potential applications to PAD. By compiling the drug information in two drug databases DrugBank and PharmGKB, we predict FDA-approved drugs whose targets are the proteins annotated as anti-angiogenic and pro-inflammatory, respectively. Examples of pro-angiogenic drugs are carvedilol and urokinase. Examples of anti-inflammatory drugs are ACE inhibitors and maraviroc. This is the first computational drug repositioning study for PAD.",
keywords = "Angiogenesis, Bioinformatics, Cardiovascular disease, Computational drug repositioning, Drug-target network, Inflammation, Peripheral arterial disease",
author = "Chu, {Liang Hui} and Annex, {Brian H.} and Popel, {Aleksander S}",
year = "2015",
doi = "10.3389/fphar.2015.00179",
language = "English (US)",
volume = "6",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "Aug",

}

TY - JOUR

T1 - Computational drug repositioning for peripheral arterial disease

T2 - Prediction of anti-inflammatory and pro-angiogenic therapeutics

AU - Chu, Liang Hui

AU - Annex, Brian H.

AU - Popel, Aleksander S

PY - 2015

Y1 - 2015

N2 - Peripheral arterial disease (PAD) results from atherosclerosis that leads to blocked arteries and reduced blood flow, most commonly in the arteries of the legs. PAD clinical trials to induce angiogenesis to improve blood flow conducted in the last decade have not succeeded. We have recently constructed PADPIN, protein-protein interaction network (PIN) of PAD, and here we combine it with the drug-target relations to identify potential drug targets for PAD. Specifically, the proteins in the PADPIN were classified as belonging to the angiome, immunome, and arteriome, characterizing the processes of angiogenesis, immune response/inflammation, and arteriogenesis, respectively. Using the network-based approach we predict the candidate drugs for repositioning that have potential applications to PAD. By compiling the drug information in two drug databases DrugBank and PharmGKB, we predict FDA-approved drugs whose targets are the proteins annotated as anti-angiogenic and pro-inflammatory, respectively. Examples of pro-angiogenic drugs are carvedilol and urokinase. Examples of anti-inflammatory drugs are ACE inhibitors and maraviroc. This is the first computational drug repositioning study for PAD.

AB - Peripheral arterial disease (PAD) results from atherosclerosis that leads to blocked arteries and reduced blood flow, most commonly in the arteries of the legs. PAD clinical trials to induce angiogenesis to improve blood flow conducted in the last decade have not succeeded. We have recently constructed PADPIN, protein-protein interaction network (PIN) of PAD, and here we combine it with the drug-target relations to identify potential drug targets for PAD. Specifically, the proteins in the PADPIN were classified as belonging to the angiome, immunome, and arteriome, characterizing the processes of angiogenesis, immune response/inflammation, and arteriogenesis, respectively. Using the network-based approach we predict the candidate drugs for repositioning that have potential applications to PAD. By compiling the drug information in two drug databases DrugBank and PharmGKB, we predict FDA-approved drugs whose targets are the proteins annotated as anti-angiogenic and pro-inflammatory, respectively. Examples of pro-angiogenic drugs are carvedilol and urokinase. Examples of anti-inflammatory drugs are ACE inhibitors and maraviroc. This is the first computational drug repositioning study for PAD.

KW - Angiogenesis

KW - Bioinformatics

KW - Cardiovascular disease

KW - Computational drug repositioning

KW - Drug-target network

KW - Inflammation

KW - Peripheral arterial disease

UR - http://www.scopus.com/inward/record.url?scp=84940942758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940942758&partnerID=8YFLogxK

U2 - 10.3389/fphar.2015.00179

DO - 10.3389/fphar.2015.00179

M3 - Article

C2 - 26379552

AN - SCOPUS:84940942758

VL - 6

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - Aug

M1 - 179

ER -